SNY|Sanofi SA|Preço:47.830|Var. %:0.34

Mais detalhes de Sanofi SA Empresa

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Informações de Sanofi SA



Código da empresaSNY

Nome da EmpresaSanofi SA

Data de listagemJul 01, 2002

CEOHudson (Paul)

Número de funcionários84587

Tipo de títulosDepository Receipt

Fim do ano fiscalJul 01

Endereço46 Avenue de la Grande Armee

CidadePARIS

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísFrance

Código postal75017

Telefone33153774000

Sitehttps://www.sanofi.com/

Código da empresaSNY

Data de listagemJul 01, 2002

CEOHudson (Paul)

Executivos da empresa Sanofi SA



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Olivier Charmeil

Executive Vice President - General Medicines, Member of the Executive Committee

--

Ms. Fabienne Lecorvaisier

Independent Director

--

Mr. Patrick Kron

Independent Director

--

Mr. Christophe Babule

Director

--

Mr. Paul Hudson, Ph.D.

Chief Executive Officer, Executive Director, Member of the Executive Committee

--

Ms. Rachel Duan

Independent Director

--

Ms. Lise Kingo

Independent Director

--

Ms. Natalie Bickford

Chief People Officer, Executive Vice President, Member of the Executive Committee

--

Ms. Julie Van Ongevalle

Executive Vice President - Consumer Healthcare, Member of the Executive Committee

--

Mr. Thomas Triomphe

Executive Vice President - Vaccines, Member of the Executive Committee

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Olivier Charmeil

Executive Vice President - General Medicines, Member of the Executive Committee

--

Ms. Fabienne Lecorvaisier

Independent Director

--

Mr. Patrick Kron

Independent Director

--

Mr. Christophe Babule

Director

--

Mr. Paul Hudson, Ph.D.

Chief Executive Officer, Executive Director, Member of the Executive Committee

--

Ms. Rachel Duan

Independent Director

--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Os dados relevantes ainda não foram divulgados pela empresa.

Por RegiãoUSD

Nome

Receita

Proporção

United States

7.99B

54.99%

Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)

3.51B

24.18%

Europe

3.03B

20.82%

Por Empresa

Por Região

Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: dom, 16 de nov

Investidores

Tipos de investidores

Investidores

Proporção

Dodge & Cox

2.83%

Fisher Investments

0.52%

Barrow Hanley Global Investors

0.29%

Managed Account Advisors LLC

0.26%

T. Rowe Price Associates, Inc.

0.24%

Outro

95.85%

Investidores

Proporção

Dodge & Cox

2.83%

Fisher Investments

0.52%

Barrow Hanley Global Investors

0.29%

Managed Account Advisors LLC

0.26%

T. Rowe Price Associates, Inc.

0.24%

Outro

95.85%

Tipos de investidores

Investidores

Proporção

Investment Advisor/Hedge Fund

4.92%

Investment Advisor

3.82%

Research Firm

0.80%

Hedge Fund

0.32%

Bank and Trust

0.10%

Family Office

0.02%

Pension Fund

0.02%

Outro

90.01%

Participação acionária institucional



Atualizado em: qui, 1 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

1280

242.12M

9.94%

-23.75M

2025Q3

1269

251.34M

10.32%

-27.29M

2025Q2

1261

264.33M

10.86%

-14.23M

2025Q1

1286

268.29M

10.62%

-13.21M

2024Q4

1263

270.44M

10.70%

-30.67M

2024Q3

1239

286.03M

11.43%

-5.72M

2024Q2

1248

275.46M

11.01%

-5.50M

2024Q1

1232

261.25M

10.33%

-7.62M

2023Q4

1213

251.25M

9.93%

-18.33M

2023Q3

1178

256.18M

10.15%

-15.97M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Dodge & Cox

68.93M

2.83%

-2.79M

-3.89%

Sep 30, 2025

Fisher Investments

12.58M

0.52%

-556.62K

-4.24%

Sep 30, 2025

Barrow Hanley Global Investors

7.13M

0.29%

-153.54K

-2.11%

Sep 30, 2025

Managed Account Advisors LLC

6.44M

0.26%

-1.04M

-13.90%

Sep 30, 2025

T. Rowe Price Associates, Inc.

5.87M

0.24%

+347.79K

+6.30%

Sep 30, 2025

Invesco Advisers, Inc.

5.16M

0.21%

-3.40M

-39.74%

Sep 30, 2025

Wellington Management Company, LLP

4.12M

0.17%

-207.27K

-4.79%

Sep 30, 2025

Putnam Investment Management, L.L.C.

3.82M

0.16%

-310.38K

-7.52%

Sep 30, 2025

Boston Partners

3.68M

0.15%

-312.03K

-7.82%

Sep 30, 2025

Mondrian Investment Partners Ltd.

3.64M

0.15%

+195.92K

+5.69%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sex, 5 de dez

Nome

Proporção

VanEck Pharmaceutical ETF

10.04%

Invesco International Dividend Achievers ETF

3.05%

Altrius Global Dividend ETF

2.41%

Brandes US Value ETF

2.14%

Putnam Focused Large Cap Value ETF

1.9%

American Century Focused Large Cap Value ETF

1.42%

ProShares Ultra Nasdaq Biotechnology

1.33%

Invesco Nasdaq Biotechnology ETF

1.32%

Invesco ESG NASDAQ Next Gen 100 ETF

0.97%

Invesco NASDAQ Next Gen 100 ETF

0.74%

Ver Mais

VanEck Pharmaceutical ETF

Proporção10.04%

Invesco International Dividend Achievers ETF

Proporção3.05%

Altrius Global Dividend ETF

Proporção2.41%

Brandes US Value ETF

Proporção2.14%

Putnam Focused Large Cap Value ETF

Proporção1.9%

American Century Focused Large Cap Value ETF

Proporção1.42%

ProShares Ultra Nasdaq Biotechnology

Proporção1.33%

Invesco Nasdaq Biotechnology ETF

Proporção1.32%

Invesco ESG NASDAQ Next Gen 100 ETF

Proporção0.97%

Invesco NASDAQ Next Gen 100 ETF

Proporção0.74%

Dividendo



Um total de 19.02B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Apr 15, 2025

SNY.NB Final Cash Dividend of gross USD 2.195331 paid on Jun 12, 2025 going ex on May 09, 2025

May 09, 2025

Jun 12, 2025

May 09, 2025

Mar 26, 2024

SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024

May 10, 2024

Jun 06, 2024

May 09, 2024

Feb 15, 2023

SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023

May 31, 2023

Jun 23, 2023

May 30, 2023

Apr 20, 2022

SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022

May 05, 2022

May 31, 2022

May 04, 2022

Mar 24, 2021

SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021

May 04, 2021

May 26, 2021

May 03, 2021

Mar 05, 2020

SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020

May 01, 2020

May 26, 2020

Apr 30, 2020

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados